Ganga Pharma FY26 revenue inches up 7% to ₹282.79 lakhs
Net profit jumps 28% to ₹10.15 lakhs; auditor issues clean opinion. Routine filing for the nano-cap.
— 1 earlier story on Ganga Pharmaceuticals Ltd. →What's new with Ganga Pharmaceuticals Ltd.
- Revenue from operations rose to ₹282.79 lakhs, up 7% from FY25.
- Net profit climbed 28% to ₹10.15 lakhs.
- Auditor issued unmodified opinion; no guidance changes.
Why this matters for Ganga Pharmaceuticals Ltd.
For a nano-cap with a ₹7-crore market cap, these results are routine and unlikely to alter the stock's trajectory. The modest growth and clean audit provide no negative surprises, but also no catalysts. The key remains how the company deploys warrant conversion proceeds.
What we're watching
- Progress on utilization of warrant conversion proceeds.
- Whether revenue growth accelerates in H1 FY27.
- Any new order wins or product launches.
The full read
Ganga Pharmaceuticals turned in a steady but unexciting FY26. Revenue inched up 7% to ₹282.79 lakhs, while net profit jumped 28% to ₹10.15 lakhs, partly due to a low base. The auditor gave an unmodified opinion, and no guidance changes were made. For a ₹7-crore market-cap company, these numbers are too small to move the needle. The real focus is on the already-disclosed warrant conversion — the company has cash to deploy, but investors have yet to see returns from that capital. Until that changes, the stock is likely to drift.